人类神经退行性疾病中的干细胞——临床转化的时机?
Stem cells in human neurodegenerative disorders--time for clinical translation?
机构信息
Laboratory of Neurogenesis and Cell Therapy, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden.
出版信息
J Clin Invest. 2010 Jan;120(1):29-40. doi: 10.1172/JCI40543.
Stem cell-based approaches have received much hype as potential treatments for neurodegenerative disorders. Indeed, transplantation of stem cells or their derivatives in animal models of neurodegenerative diseases can improve function by replacing the lost neurons and glial cells and by mediating remyelination, trophic actions, and modulation of inflammation. Endogenous neural stem cells are also potential therapeutic targets because they produce neurons and glial cells in response to injury and could be affected by the degenerative process. As we discuss here, however, significant hurdles remain before these findings can be responsibly translated to novel therapies. In particular, we need to better understand the mechanisms of action of stem cells after transplantation and learn how to control stem cell proliferation, survival, migration, and differentiation in the pathological environment.
基于干细胞的方法作为神经退行性疾病的潜在治疗方法受到了广泛关注。事实上,在神经退行性疾病的动物模型中移植干细胞或其衍生物可以通过替代丢失的神经元和神经胶质细胞以及通过介导髓鞘再生、营养作用和调节炎症来改善功能。内源性神经干细胞也是潜在的治疗靶点,因为它们在受到损伤时会产生神经元和神经胶质细胞,并且可能受到退行性过程的影响。然而,正如我们在这里讨论的那样,在这些发现能够负责任地转化为新的治疗方法之前,仍然存在重大障碍。特别是,我们需要更好地了解移植后干细胞的作用机制,并学习如何在病理环境中控制干细胞的增殖、存活、迁移和分化。